Kupando Closes €10M Round to Advance Immune Therapy
TLR Agonists Activate a Different MoA from Checkpoint Inhibitors — Additive Effect
Berlin-based biotech Kupando has closed an additional €10 million in Series A funding, bringing its total Series A raise to €23 million. According to the company's press release, the round was again led by Remiges Ventures and co-led by LifeCare Partners, with all existing investors participating alongside new backer Carma Fund.
The company is developing KUP101, a dual TLR 4 and 7 agonist designed to activate the body's innate immune system and trigger trained immunity. The approach targets both solid tumors and infectious diseases, including antimicrobial-resistant infections. The AMR program receives sponsorship from Germany's Federal Ministry of Research, Technology and Space.
Fresh capital will fund a Phase 1b clinical study of KUP101 in advanced solid tumors and accelerate preclinical work in infectious diseases. CEO and founder Johanna Holldack called the funding "a testament to the potential of our innovative dual TLR agonist platform." New investor Carma Fund's managing partner Martin Raditsch highlighted the strength of the round given current market headwinds, pointing to investor confidence in Kupando's science and team.
Kupando was founded on the observation that animals relying solely on innate immunity show remarkable natural resilience, an insight Holldack has turned into a therapeutic strategy with potential across oncology and infectious disease.
Thinking about launching a business, setting up premises, or creating partnerships in Berlin?
We invite you to contact us.
Our team is ready to help you with our free consultation services.